HEOIX
Price
$15.95
Change
-$0.48 (-2.92%)
Updated
Dec 18 closing price
RWIBX
Price
$62.66
Change
-$1.77 (-2.75%)
Updated
Dec 18 closing price
Ad is loading...

HEOIX vs RWIBX

Header iconHEOIX vs RWIBX Comparison
Open Charts HEOIX vs RWIBXBanner chart's image
Hartford Climate Opportunities I
Price$15.95
Change-$0.48 (-2.92%)
VolumeN/A
CapitalizationN/A
American Funds Capital World Gr&Inc R2
Price$62.66
Change-$1.77 (-2.75%)
VolumeN/A
CapitalizationN/A
HEOIX vs RWIBX Comparison Chart
Loading...
View a ticker or compare two or three
VS
HEOIX vs. RWIBX commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HEOIX is a Hold and RWIBX is a Buy.

FUNDAMENTALS
Fundamentals
RWIBX has more cash in the bank: 121B vs. HEOIX (131M). RWIBX pays higher dividends than HEOIX: RWIBX (1.05) vs HEOIX (0.63). HEOIX was incepted earlier than RWIBX: HEOIX (9 years) vs RWIBX (23 years). HEOIX is a more actively managed with annual turnover of: 75.00 vs. RWIBX (27.00). RWIBX has a lower initial minimum investment than HEOIX: RWIBX (250) vs HEOIX (2000). RWIBX (11.34) and HEOIX (10.87) have marching annual gain over last year. HEOIX return over 5 years is better than : 50.89 vs. RWIBX (29.64).
HEOIXRWIBXHEOIX / RWIBX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence9 years23 years-
Gain YTD8.3779.78186%
Front LoadN/AN/A-
Min. Initial Investment2000250800%
Min. Initial Investment IRAN/AN/A-
Net Assets131M121B0%
Annual Yield % from dividends0.631.0560%
Returns for 1 year10.8711.3496%
Returns for 3 years1.308.4115%
Returns for 5 years50.8929.64172%
Returns for 10 yearsN/A44.22-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
LITM0.180.03
+17.46%
Snow Lake Resources Ltd
NUVB2.810.12
+4.46%
Nuvation Bio
ENTG109.362.65
+2.48%
Entegris
ARQ7.01-0.04
-0.57%
Arq
PTCT47.02-1.59
-3.27%
PTC Therapeutics